A retrospective cohort study analyzed the real-world implementation of a hospital-wide antimicrobial therapeutic drug monitoring (TDM) program launched in June 2024 at a Chinese tertiary hospital. The analysis included 2,316 plasma drug concentration measurements from 1,928 inpatients. No comparator group was reported, and the study's primary outcome was not specified.
The main findings revealed significant inter-departmental heterogeneity in TDM implementation. For instance, TDM utilization was 91.95% in the Emergency Intensive Care Unit (EICU) but 0% in the Pediatrics department. Overall, only 50.3% of measured drug concentrations were within the therapeutic range. Attainment rates varied by drug class: they were 31.47% for the time-dependent agent piperacillin and 86.09% for the concentration-dependent agent moxifloxacin. Subtherapeutic concentrations were predominantly clustered in hematology patients, while supratherapeutic concentrations were concentrated in ICU patients. The study also noted that a trough concentration-based monitoring strategy was inadequate for addressing complex pharmacokinetics in critically ill patients.
Safety and tolerability data were not reported. Key limitations include the retrospective, single-center design, which limits the generalizability of the findings. The lack of a comparator group and unreported primary outcomes also constrain the interpretation of the program's effectiveness. For practice, this study provides a snapshot of the challenges in implementing consistent, hospital-wide TDM, showing that even with a program in place, therapeutic target attainment can be low and highly variable across specialties.
View Original Abstract ↓
Therapeutic Drug Monitoring (TDM) is pivotal for optimizing antimicrobial efficacy and managing drug-resistant infections. However, its real-world implementation patterns, particularly the heterogeneity in initial hospital-wide application within large Chinese general hospitals, have not been systematically evaluated.
This retrospective study was conducted in a representative Chinese tertiary hospital to assess its hospital-wide antimicrobial TDM program launched in June 2024. The analysis included 2,316 plasma drug concentration measurements from 1,928 inpatients between October and December 2024, primarily evaluated based on trough concentrations.
The study revealed significant inter-departmental heterogeneity in TDM implementation. Utilization was high in intensive care units (e.g., EICU: 91.95%) and infection-related departments, but critically low in non-intensive care settings (e.g., Pediatrics: 0%). Overall, only 50.3% of drug concentrations were within the therapeutic range, with time-dependent antimicrobials (e.g., piperacillin attainment: 31.47%) performing significantly worse than concentration-dependent agents (e.g., moxifloxacin attainment: 86.09%). Subtherapeutic concentrations were predominantly clustered in hematology patients, while supratherapeutic concentrations were concentrated in ICUs. The study also demonstrated the inadequacy of a trough concentration-based monitoring strategy for addressing the complex pharmacokinetics in critically ill patients.
This study provides a critical snapshot of the heterogeneous implementation and systemic inequities in the initial rollout of a hospital-wide antimicrobial TDM program. The findings highlight a significant gap between specialized technique and equitable public health practice. Addressing these implementation disparities requires tailored strategies, multidisciplinary collaboration, and refined monitoring approaches to optimize antimicrobial stewardship and ensure all patients benefit from precision dosing.